Hasegawa Takeshi, Suzukamo Yoshimi, Akizawa Tadao, Fukuhara Shunichi
Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan.
Nihon Jinzo Gakkai Shi. 2008;50(1):42-50.
The SF-36v2 (version 2 of the SF-36 health survey) is an instrument used worldwide to measure the generic health-related quality of life (HQOL). The SF-36v2 has "standard" and "acute" forms, in which respondents are asked about the previous month and the previous week, respectively. The standard form of the Japanese-language version of the SF-36v2 has already been validated, but the acute form has not. We evaluated the validity and reliability of the Japanese SF-36v2 acute form in patients with chronic kidney disease (CKD).
Cross-sectional data from 210 CKD patients who enrolled a clinical trial of a long-acting erythropoiesis stimulating agent (darbepoetin alfa) were analyzed. The feasibility of question items and distributions of the response choices were examined. Cronbach's alpha was computed to assess internal-consistency reliability. Construct validity was evaluated with tests of convergent and discriminant validity, and with factor analysis. Validity with regard to reference groups for the severity of anemia and for performance states was also assessed.
There were few missing data and the distribution of response choices did not differ between the acute form and the standard form. Values of Cronbach's alpha for the acute form sub-scales were sufficient. The percentages of items that passed the tests of convergent validity and discriminant validity were 100% and 98.7%, respectively. Factor analysis identified the same components in the acute form as in the standard form. "Dose-response" relationships were found between the sub-scale scores on the acute form and the severity of anemia, and also between those scores and performance states.
The Japanese SF-36v2 acute form can be expected to provide valid and reliable HQOL data in CKD patients.
SF-36v2（健康调查简表第2版）是一种在全球范围内用于测量一般健康相关生活质量（HQOL）的工具。SF-36v2有“标准”和“急性”两种形式，分别询问受访者前一个月和前一周的情况。日语版SF-36v2的标准形式已经得到验证，但急性形式尚未验证。我们评估了日语版SF-36v2急性形式在慢性肾脏病（CKD）患者中的有效性和可靠性。
分析了210例参与长效促红细胞生成刺激剂（阿法达贝泊汀）临床试验的CKD患者的横断面数据。检查了问题项目的可行性和回答选项的分布情况。计算Cronbach's α系数以评估内部一致性可靠性。通过收敛效度和区分效度测试以及因子分析来评估结构效度。还评估了与贫血严重程度和功能状态参考组相关的效度。
缺失数据很少，急性形式和标准形式的回答选项分布没有差异。急性形式子量表的Cronbach's α系数值足够。通过收敛效度测试和区分效度测试的项目百分比分别为100%和98.7%。因子分析在急性形式中识别出与标准形式相同的成分。在急性形式的子量表得分与贫血严重程度之间以及这些得分与功能状态之间发现了“剂量反应”关系。
日语版SF-36v2急性形式有望为CKD患者提供有效且可靠的HQOL数据。
